SCHEMBL3203740

SCHEMBL3203740

CC(C)N(C(C)C)S(=O)(=O)c1cc[c]cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
VCAM1 P19320 1/20 0.41
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ESR1 P03372 1/20 0.33
AGER Q15109 1/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
HTT P42858 2/20 0.32
GLA P06280 1/20 0.32
CA1 P00915 2/20 0.31
CA2 P00918 2/20 0.31
CA5A P35218 2/20 0.31
CA7 P43166 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3202885 0.83 LMNA (0.35) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL182553 0.77 ALDH1A1 (0.54) SMN1; SMN2ALDH1A1MAPTKDM4EVCAM1
SCHEMBL4613713 0.77 APOBEC3G (0.54) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL3181881 0.76 TAS2R14 (0.58) SMN1; SMN2ALDH1A1GAALMNATAS2R14
SCHEMBL12989147 0.74 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL11135901 0.74 TSHR (0.50) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL2936178 0.74 SMN1; SMN2 (0.50) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL2332262 0.74 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1MAPTKDM4EGAA
SCHEMBL517898 0.73 ALDH1A1 (0.33) ALDH1A1
SCHEMBL1085990 0.72 LMNA (0.64) SMN1; SMN2ALDH1A1MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678907-B2 Halogenation of rylen-carboximides with elementary halogen in a two-phase mixture comprising an organic solvent and water, wherein formed halogen hydroxide is continuously removable from the organic solvent BASF AKTIENGESSELLSCHAFT (DE) 2010-03-16 US disclosed
EP-1802622-B1 HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT BASF SE (DE) 2008-04-23 EP disclosed
US-20080058526-A1 Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent BASF AKTIENGESELLSCHAFT (DE) 2008-03-06 US disclosed
EP-1802622-A1 HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT BASF AKTIENGESELLSCHAFT (DE) 2007-07-04 EP disclosed
WO-2006037539-A1 HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT BASF AKTIENGESELLSCHAFT (DE) 2006-04-13 WO disclosed
US-6190824-B1 POLYMERIZABLE MONOMER, A PHOTOPOLYMERIZATION INITIATOR, AND A DIAZONIUM SALT HAVING A SPECIFIC, BORON ANION PORTION FUJI PHOTO FILM CO., LTD. (JP) 2001-02-20 US disclosed
US-5663386-A REACTION WITH AQUEOUS ALKALINE SOLUTION PRODUCES COLOR WHICH PASSES INTO AQUEOUS PHASE BASF AKTIENGESELLSCHAFT (DE) 1997-09-02 US disclosed
EP-0689575-B1 ANTHRAQUINONES AS MARKING AGENTS FOR MINERAL OILS BASF AG (DE) 1997-02-05 EP disclosed
EP-0689575-A1 ANTHRAQUINONES AS MARKING AGENTS FOR MINERAL OILS BASF AG (DE) 1996-01-03 EP disclosed
WO-1994021752-A1 ANTHRAQUINONES AS MARKING AGENTS FOR MINERAL OILS BASF AKTIENGESELLSCHAFT (DE) 1994-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058526-A1 Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent CYP8B1, HACL2, CTRB2 SMN1; SMN2 3469/4885ALDH1A1 1379/4885MAPT 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.